Renal Diseases Drug Development Pipeline Review: 2018 – Therapeutics Under Development and Key Players Involved –

Diseases Drug Development Pipeline Review, 2018”
report has
been added to’s offering.

Renal Diseases Drug Development Pipeline Review, 2018
provides an overview of the pipeline landscape for renal diseases.

It provides comprehensive information on the therapeutics under
development and key players involved in therapeutic development for
chronic kidney disease (chronic renal failure), kidney fibrosis,
polycystic kidney disease and end-stage kidney disease (end-stage renal
disease), and features dormant and discontinued products.

  • Chronic kidney disease is the slow loss of kidney function over time:
    There are 58 products in development for this indication.
  • Accumulation of extracellular matrix in the kidney: There are 49
    products in development for this indication.
  • Polycystic kidney disease: There are 26 products in development for
    this indication.
  • End-stage kidney disease: There are five products in development for
    this indication.

Molecular targets in development for renal diseases include growth
factor receptors, chemokines and kinases. Companies operating in this
pipeline space include Angion Biomedica, Prolong Pharmaceuticals and


  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage
    of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within
    this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to
    have happened in this disease area?

Topics Covered

1 Table of Contents

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

Companies Profiled

  • AdAlta Ltd
  • Allena Pharmaceuticals Inc
  • apceth Biopharma GmbH
  • Arch Biopartners Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • Corvidia Therapeutics Inc
  • DiaMedica Therapeutics Inc
  • DiscoveryBiomed Inc
  • DURECT Corp
  • Epigen Biosciences Inc
  • Galectin Therapeutics Inc
  • GenKyoTex SA
  • GNI Group Ltd
  • iBio Inc
  • IC-MedTech Inc
  • Ipsen SA
  • KBP BioSciences Co Ltd
  • Kidney Fibrosis
  • ManRos Therapeutics
  • Mironid Ltd
  • NovaTarg Therapeutics Inc
  • Novo Nordisk AS
  • OPKO Health Inc
  • Opsidio LLC
  • Otsuka Holdings Co Ltd
  • Pharmaxis Ltd
  • Q BioMed Inc
  • Redx Pharma PLC
  • Unity Biotechnology Inc
  • Vascular Biogenics Ltd
  • Vascular BioSciences
  • Vicore Pharma AB
  • and more…

For more information about this report visit

Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Drug
, Liver
and Kidney Disorders Drugs